Improved Overall Survival in Melanoma with Combined Dabrafenib and TrametinibCaroline Robert, Dirk Schadendorf, Bogusława Karaszewska et al.|New England Journal of Medicine|2014Cited by 2.7k
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trialH. Miles Prince, M. D’Incan, Erin Zagadailov et al.|The Lancet|2017Cited by 580
Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT)Richard D. Carvajal, Paul Nathan, Sophie Piperno‐Neumann et al.|Journal of Clinical Oncology|2018Cited by 274
Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trialJean‐Jacques Grob, Caroline Robert, Mayur M. Amonkar et al.|The Lancet Oncology|2015Cited by 264
Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trialMatteo S. Carlino, Adil Daud, Georgina V. Long et al.|European Journal of Cancer|2018Cited by 98